April 2018 VOL 9, NO 4

Letters from Lillie

Promoting Clinical Trials: Navigator’s Role in Providing “First Hope” to Patients

Lillie D. Shockney, RN, BS, MAS, ONN-CG 

Dear Navigators, Social Workers, Administrators, and Clinical Staff, Our 2017 ONE Award winner, Laura Mulderrig, BSN, RN, OCN, was recently asked about her work on the clinical trials unit and [ Read More ]

Interview with the Innovators

Interview: Oncology Care Coordination in Two Settings

Lisa Allison, MS, RN, OCN; Jeanne Melton, RN, OCN, ONN-CG 

An Interview with Lisa Allison, MS, RN, OCN, University of Colorado Health, and Jeanne Melton, RN, OCN, ONN-CG, Karmanos Cancer Institute The Academy of Oncology Nurse & Patient Navigators published [ Read More ]

Interview with the Innovators

Interview: Financial Navigation and Its Role in Cancer Care

Clara Lambert 

An Interview with Oncology Financial Navigator Clara Lambert of Cowell Family Cancer Center Emerging pharmacologic therapies used for the treatment of oncology are being developed and approved at an accelerated [ Read More ]

Clinical Research

Navigating the Complex Terrain of Clinical Trials

Lavinia Dobrea, RN, MS, OCN; Lucy J. Gansauer, MSN, RN, OCN, CCRP 

As navigators, we strive to bring the highest quality of care to our patients by including clinical research nurses as critical members of the team. Although there are clear role [ Read More ]

ASH Conference Highlights

CAR T-Cell Therapy Targeting B-Cell Maturation Antigen Shows “Impressive” Results in Multiple Myeloma

Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly [ Read More ]

ASH Conference Highlights

Acute Myeloid Leukemia Treatment Episodes Linked to Significant Economic Burden

A retrospective analysis of a large commercial payer database has demonstrated a link between various treatment episodes of acute myeloid leukemia (AML) and substantial economic burden. According to data presented [ Read More ]

ASH Conference Highlights

A New Combination as First-Line Regimen in Advanced Hodgkin Lymphoma?

Using a regimen with brentuximab vedotin (Adcetris) added to doxorubicin, vinblastine, and dacarbazine (A+AVD) instead of the standard regimen with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as frontline treatment for [ Read More ]

ASH Conference Highlights

Venetoclax plus Rituximab New Chemotherapy-Free Standard for Chronic Lymphocytic Leukemia

Venetoclax (Venclexta) plus ri­tuximab (Rituxan) achieved superior progression-free survival (PFS) and overall survival (OS) compared with standard-of-care bendamustine (Treanda/Bendeka) plus ri­tuximab in patients with relapsed or refractory chronic lymphocytic leukemia [ Read More ]

ASH Conference Highlights

Sotatercept, a First-in-Class Agent, Improves Hemoglobin Levels in Anemic Patients with Myelofibrosis

Sotatercept, an investigational activin receptor IIA ligand trap, when used alone or in combination with ruxolitinib (Jakafi), safely increases hemoglobin levels in patients with myeloproliferative neoplasm–associated myelofibrosis, according to data [ Read More ]

ASH Conference Highlights

ASH Recaps “Phenomenal” Year for Acute Myeloid Leukemia Drug Approvals

Although there have been major advancements in the treatment of hematologic malignancies in recent years, according to Richard Pazdur, MD, Director, FDA’s Oncology Center of Excellence, the number of agents [ Read More ]

ASH Conference Highlights

Which Combination Immunotherapies to Use, and When? Despite Improved Response Rates, Serious Toxicity Remains a Concern

As single-agent immunotherapies continue to show promising results, the challenge is now to determine which combination regimens with immunotherapies can improve outcomes. According to data presented at ASH 2017, 3 [ Read More ]

ASH Conference Highlights

Direct Oral Anticoagulants: New Standard of Care for VTE in Patients with Cancer?

Direct oral anticoagulants (DOACs) may replace low molecular weight heparin (LMWH) as standard of care for management of venous thromboembolism (VTE) in cancer patients, judging by the results of 2 [ Read More ]

ASH Conference Highlights

CAR T-Cell Therapy Makes Significant Inroads in Lymphoma: Kymriah and Yescarta Show Durable Remissions

CD19-directed chimeric antigen receptor (CAR) T-cell therapy continues to show excellent and durable responses in patients with lymphoma who have no other treatment options. Two studies presented at ASH 2017 [ Read More ]